To test whether T.eff score predicts the efficacy of immunotherapy in human tumors, we analyzed a public dataset of patients with advanced bladder cancer (BLCA) before and after anti–PD-1 therapy. Here, PDCD1 is linked to bladder transitional cell carcinoma.